Source: Annual Congress 2009 - Pathological remodelling in chronic lung disease: from epithelial-mesenchymal transition to cellular activation
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. M. Zielonka, U. Demkow, E. Radzikowska, M. Filewska, B. Bialas, K. Zycinska, J. Kus, A. Wardyn, E. Skopinska-Rozewska (Warsaw, Poland). Angiogenic activity of sera from patients with various types of pulmonary fibrosis in relation to pulmonary functions. Eur Respir J 2009; 34: Suppl. 53, 3099

Member's Comments

No comment yet.

Related content which might interest you: Role of IL-11 in vascular function of pulmonary fibrosis patients Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 Relationships between angiogenic activity of sera from interstitial lung disease (ILD) patients and lung function tests Source: Eur Respir J 2002; 20: Suppl. 38, 106s Year: 2002 TNFα and INFγ inducing capacity of sera from interstitial lung diseases (ILD) patients in relation to its angiogenic activity Source: Eur Respir J 2001; 18: Suppl. 33, 410s Year: 2001 Inflammatory markers in cystic fibrosis patients with different values of pulmonary function tests Source: Eur Respir J 2002; 20: Suppl. 38, 528s Year: 2002 The markers of inflammatory process activity and fybrogenesis activity in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease I Year: 2012 Evaluation of functional capacity and pulmonary functions during acute pulmonary exacerbation in children with cystic fibrosis Source: Virtual Congress 2020 – Exercise tolerance and functional status across respiratory diseases Year: 2020 Procoagulant and antifibrynolitic activities strongly correlate with fibrosis and tissue turn-over markers in patients with active idiopathic pulmonary fibrosis and hypersensitivity pneumonitis Source: Annual Congress 2008 - Clinical aspects of interstitial lung disease Year: 2008 Clinical characteristics and pulmonary function in patients with pulmonary fibrosis assessed for lung transplant Source: Annual Congress 2010 - Pre-operative evaluation and post-operative problems after lung transplantation Year: 2010 Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 VEGF expression does not differentiate between idiopathic pulmonary fibrosis and pulmonary sarcoidosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007 Correlation between physical activity and prognostic markers in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Differential expression of telomerase activity in patients with autoimmune pulmonary fibrosis in BALF Source: Annual Congress 2010 - Different patterns of diffuse parenchymal lung disease Year: 2010 Determination of pulmonary hypertension degree in patients with interstitial lung diseases Source: Annual Congress 2010 - Different patterns of interstitial lung disease Year: 2010 Increased polysialylation in lung tissue of patients with idiopathic pulmonary fibrosis Source: Annual Congress 2011 - Cell biology of lung disease Year: 2011 Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema Source: Eur Respir J 2011; 37: 176-183 Year: 2011 Predictors of physical activity in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Best abstracts in physical activity and telemedicine Year: 2016 Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003 Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 PP309 – Effect of elexacaftor-tezacaftor-ivacaftor on pulmonary and endothelial function in a patient with advanced cystic fibrosis Source: ERS Lung Science Conference 2021 Year: 2021 Cytokines status, endothelial function in patients with pulmonary diseases Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases Year: 2008